FIRE-12NCT07844057
First-line Treatment in Locally Advanced or Metastastic Small Bowel Adenocarcinoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 2 versions: 2 with changes below. See every version on ClinicalTrials.gov ↗
- Notable Recruitment opened
- Start date changed from estimate of Oct 1, 2026 to Oct 22, 2026
- Secondary endpoints: 4 to 5
- Site details revised at 16 of 16 sites
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Median Progression-free survival (PFS)
Timeframe: 84 months
Secondary (5)
Median Overall survival (OS)
Objective response rate (ORR)
Patient Safety
Quality of life (QoL)
Depth of response (DpR),
Arms and interventions
Treatment arm A: mFOLFIRINOX every two weeksOther
* oxaliplatin 85 mg/m² 2 hours intravenously * irinotecan 150 mg/m² 60-90 minutes intravenously * leucovorin 400 mg/m² 2 hours intravenously * 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion
Treatment arm B: FOLFOX every two weeksOther
* oxaliplatin 85 mg/m² 2 hours intravenously * leucovorin 400 mg/m² 2 hours intravenously * 5-fluorouracil 400 mg/m² intravenous bolus injection * 5-fluorouracil 2400 mg/m² 46 hours continuous intravenous infusion
Drugs: mFOLFIRINOX versus FOLFOX chemotherapy
Sites
16 sites in 1 country